



**SOLVE  
ON.**

## **Incyte Celebrates the 2025 MPN Heroes®, Extraordinary Individuals and Organizations Making an Impact on the Myeloproliferative Neoplasm (MPN) Community**

**WILMINGTON, Del. – December 5, 2025** – Incyte is honored to announce the 2025 MPN Heroes®, a recognition program which celebrates individuals and organizations committed to improving the lives of people impacted by myeloproliferative neoplasms (MPNs). From healthcare professionals providing compassionate care to advocates championing patient voices, these Heroes bring understanding, strength and hope to the MPN community.

“Through the MPN Heroes Recognition Program, Incyte has honored more than 90 individuals and organizations that have created community, advanced solutions and, in some cases, progressed treatment options for people living with MPNs,” said Mohamed Issa, Executive Vice President and Head of U.S. Oncology at Incyte. “Incyte joins these Heroes in our shared commitment to the community, and we applaud their superb efforts to go above and beyond to make a difference for those impacted by MPNs.”

This year’s MPN Heroes will be celebrated at an event on Friday, December 5, 2025, at the 67<sup>th</sup> American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. In addition to recognizing all the extraordinary efforts of our Heroes whose work makes a lasting impact on the MPN community, this year’s event will include a poster session from leading advocacy groups.

An independent judging panel selected eight individuals and organizations that are shaping MPN advocacy and care as the 2025 MPN Heroes:

- **Haris Ali, M.D.**, is an MPN Hero for his unwavering dedication to people living with MPNs and commitment to providing compassionate, patient-focused care. Dr. Ali is a hematologist-oncologist, Associate Professor and MPN Section Leader at City of Hope, where he devotes his time and expertise to personalizing treatment plans, engaging in cutting-edge clinical trials and providing emotional support. He profoundly impacts the lives of his patients, earning him recognition as a transformative figure in the MPN community.
- **Aïcha Diallo, M.P.H., C.H.E.S.**, is an MPN Hero for her integral and meaningful work as an advocate for patient communities, including patients and caregivers impacted by MPNs. As Vice President of Programs at the Patient Empowerment Network, she is committed to providing resources, enhancing health literacy and fostering equitable access to care. Her support for people living with MPNs is palpable, and Aïcha has left a lasting mark of support for countless patients and caregivers.
- **Salman Fazal, M.D.**, is an MPN Hero for his steadfast leadership in providing personalized and compassionate care to people living with MPNs. As the Director of Cell Transplantation in the Division of Hematology and Cellular Therapy at the Allegheny Health Network Cancer Institute and Assistant Professor in the

Department of Medicine at Temple University School of Medicine, Dr. Fazal established the Institute's MPN clinical program and is recognized for transforming patient lives through top-tier treatment, pioneering research in key clinical trials and educating patients and future hematologists.

- **Katherine Mast Hagemann, B.S.N., Ambulatory R.N.**, is an MPN Hero for her outstanding patient-first care for people living with MPNs. Katherine works at Moffitt Cancer Center where she prioritizes empathetic conversations and emotional support, ensuring patients feel heard and understood at every appointment. Leveraging a unique approach, she combines her expert knowledge of MPNs and treatment options with genuine passion, setting an example for enhancing the MPN treatment experience.
- **Julie Huynh-Lu** is an MPN Hero for the exceptional care, advocacy and education she provides to people living with MPNs. As a physician assistant and Supervisor, Advanced Practice Provider at MD Anderson Cancer Center, Julie established and manages the MPN/Survivorship Clinic to support patients, educates colleagues to inspire continuous learning, and offers expert guidance to ensure top-tier care for those affected by MPNs. Her trusted knowledge of MPNs and dedication to providing care has profoundly impacted those she works with and who are under her care.
- **Jo Ann Mannino** is an MPN Hero for her unwavering dedication to advocating and supporting patients and families impacted by MPNs. Jo Ann, who lives with polycythemia vera, is a Board Member and Treasurer of the MPN Education Foundation and a support group leader through MPN-NET in New York City. She spends her time advocating for continued research and treatment options in MPNs. Jo Ann has a passion for ensuring fellow patients have access to exceptional care and quality information about MPNs.
- **Kapila Vigés** is an MPN Hero for her outstanding impact and dedication to furthering research, education and advocacy within the MPN community. As Chief Executive Officer of the MPN Research Foundation, Kapila displays transformative leadership in expanding patient engagement, increasing awareness and fostering partnerships to improve the lives of people living with MPNs. She is committed to bridging the gap between patients and the medical and pharmaceutical communities to ensure that patient voices are at the center of research and development for MPNs.
- **The Washington University Team MPN**, a group comprised of four dedicated clinical research coordinators, is an MPN Hero for its exceptional dedication to providing seamless, compassionate care for those living with MPNs. Team MPN, which includes Nicole Gaudin, Karyn Gordon, Maggie Cox and Julie White, facilitates access to cutting-edge clinical trials, provides attentive care to patients, and fosters a welcoming environment that extends beyond standard care.

Nominations for the 2025 MPN Heroes Recognition Program were evaluated by an independent judging panel comprised of five MPN community experts and advocates: Steven Applebaum, M.D., Hematologist, Medical Oncologist, University of California Los Angeles Health; Patrick Buxton, R.N., Clinical Nurse Manager, Fred Hutchinson Cancer Center; Sara Douglas, M.S.N., R.N., O.C.N., Director of Patient Engagement, MPN Research

Foundation; Marina Kremyanskaya, M.D., Ph.D., Associate Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, Medical Director, Inpatient Oncology, The Mount Sinai Hospital; and Mickey Tumlin, patient advocate.

Nominations are now open for the 2026 MPN Heroes Recognition Program. To nominate an outstanding individual or organization making a positive impact on the MPN community, complete the submission form at <https://incyte.mpnheroes.com/nominate-form>.

To learn more about the MPN Heroes Recognition Program, visit <https://incyte.mpnheroes.com/>.

### **About Myeloproliferative Neoplasms**

Myeloproliferative neoplasms (MPNs) are a closely related group of blood cancers in which the bone marrow functions abnormally. The bone marrow is where the body's blood cells are made. MPNs are progressive blood cancers that can strike anyone at any age, but they are more common in older adults. Estimates of the prevalence of MPNs vary, but analysis of claims data suggests there may be as many as 200,000 people in the U.S. living with the most prevalent MPNs: myelofibrosis, polycythemia vera or essential thrombocythemia (ET).<sup>1</sup>

### **About Incyte**

A global biopharmaceutical company on a mission to *Solve On*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit [incyte.com](https://incyte.com) or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

###

#### **Contacts:**

##### **Media**

[media@incyte.com](mailto:media@incyte.com)

##### **Investors**

[ir@incyte.com](mailto:ir@incyte.com)

---

<sup>1</sup>Data on file